Andy Reilly
08 May 2017
Re: Diggle buys again..... TP - its not just you - the world really is going crazy - at least the French didnt go for the FN and Le Pen - but we do have Trump, Brexit, and a lot of other noodleheadery ++++!
The Potter
05 May 2017
Re: Diggle buys again..... And again today, but quantity not worth mentioning and I certainly cannot be bothered to point out that is Friday again 
What is going on here? Why bother to report these miniscule director purchases. Why in 3 out of 4 recent director buys have been reported on a Friday (Oops, sorry!) Why do I have an iii advert in front of this text box?Is everyone going crazy, or is it just me?
dave297
04 May 2017
Re: Diggle buys again..... Looks like he bought the 200k shares which were announced as disposed of over the last few days by another large holder.If 2017 proves to be transformational, in terms of increasing revenues from our ongoing business,the launch of a stroke test later this year & someone ( anyone ( at very long last ) developing an AD test using our IP, our SP is likely to be much higher than 5p.Additionally our new Commercial Director must have impressed all concerned at his various interviews & I assume that he expects to justify his cost by bringing in more deals.I have not bought any more shares since the placing although I may consider "averaging down2 if some of my other more significant investments put on a bit of a spurt over the coming weeks.
geony
04 May 2017
New Licensing Program Facilitates Adoption of Tandem Mass Tag Technology New Licensing Program Facilitates Adoption of Tandem Mass Tag TechnologyCARLSBAD, Calif., May 4, 2017 /PRNewswire/ -- Research service providers and their customers are now set to benefit from a new licensing program specifically designed to facilitate and optimize the use of the Thermo Scientific™ Tandem Mass Tag™ protein identification and quantitation technology.The Thermo Fisher Scientific licensing program enables service providers to leverage the power of Thermo Scientific™ TMT™ technology to cater to the analytical needs of their customers for more reproducible quantitative proteomics. Cell Signaling Technology (CST), a specialized provider of research products and services and an early licensee, is already realizing the benefits of the quantitative multiplex technology."There is an increased market demand for the unique analytical capabilities of the TMT technology, as well as for service providers with the necessary skills and equipment to perform that type of analysis. We are very excited about growing the use of this technology and having the ability to offer it through CST's service business," said Navid Haghdoost, director, Protein Biology Product Management, Thermo Fisher Scientific.The TMT technology uses tandem mass spectrometry (MS/MS) to provide consistent and accurate simultaneous identification and quantitation of proteins in up to 10 different samples derived from cells, tissues or biological fluids. The technology features an enhanced multiplex capability resulting in fewer missing quantitative values as the level of TMT multiplexing increases."CST is pleased to license TMT technology from Thermo Fisher Scientific, which will add power to our proteomics services by delivering unparalleled quantitative protein analysis. We expect this technology will enable us to help our pharma and academic customers accelerate their pre-clinical discovery research," said Roberto Polakiewicz, chief scientific officer at CST.For more information about TMT technology, please visit: www.thermofisher.com/TMTAbout CSTCell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing the world's highest quality, innovative, research and diagnostic products to accelerate biological understanding and enable personalized medicine. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.SOURCE Thermo Fisher Scientific Inc.[link]
Andy Reilly
04 May 2017
Re: Diggle buys again..... TP - many thanks for your post - I remain baffled by the situation, but thanks again, and I wish you lots of success with PRM - ATB
The Potter
04 May 2017
Re: Diggle buys again..... Hi AR,You're not the only one who is confused!As far as I remember the relationship between Thermo Fisher and PRM has never been exclusive, and could have been detrimental to PRM (and CP) in the early years.However, in the long term, it could work out well for PRM as TF is such a big player in the US.Sometimes I find it difficult to assess PRM management's (both old and new) strategy.In the past we had the old CP blather. Now we hear next to nothing. No updates on potential money spinning deals nor drug development, and whatever happened to Sensiderm?I have put my money into believing that the market for biomarkers is expanding. There is already some indication that revenue is increasing in this 'transformational' year, if one can re-believe in statements from CP! I see no other major income streams for PRM.
Andy Reilly
03 May 2017
Re: Diggle buys again..... Hi TP - I have to say that Thermo F seem to me to be using their dominance in the field to contain PRM's SP, and dont seem to be too interested in supporting it or getting it higher, or at least halting the long term poor performance of PRM. I did think that IF PRM were to prove valuable and ground breaking Thermo F would be a likely buyer of PRM, BUT they have had their chances, and dont seem to have taken them, OR maybe it will come about soon! Its all rather confusing, and I dont pretend to be anyting but confused with PRM, BUT...IF PRM is to prove so valuable/innovative, surely Thermo would have made its move by now????? ARPS - I'd be interested to hear your view on PRM as a likely target for Thermo - I remain baffled!
The Potter
03 May 2017
Re: Diggle buys again..... AR,Maybe I'm wrong, but sentiment seems to be improving in the diagnostic biomedical sector.I base my judgement on the huge success of certain US companies that operate in this field.PRM are in a good position (through Thermo Fisher) to take advantage of this trend.
Andy Reilly
03 May 2017
Re: Diggle buys again..... TP - well it looks like Digle's call isnt bad at all, as sentiment seems to be improving - PRM still a lot to prove, but that little chart offer hope things are on the mend - Diggle is in for the long term, so most unlikely to lock in any profits soon I would have thought! Hope all goes well -
The Potter
03 May 2017
Diggle buys again..... Only another 100,000, but midweek notification is an improvemen
The Potter
30 Apr 2017
Re: Technical Events Dave297,Agreed, but that was not my point.He bought a token number of shares. Why I do not know, but director buying at such low levels is normally to persuade other punters to buy.To give news on a Friday is hardly a good idea.This was the second time PRM have been guilty of poor timing in this respect!
dave297
29 Apr 2017
Re: Technical Events Not worth over thinking Diggle spending £5k on 100k shares when he owns approaching 20%-the purchase was not significant enough to reduce his average.It would be more significant if he took his holding up to 29.99 %
The Potter
29 Apr 2017
Technical Events AR,One for you:The following alerts have been triggered. Alert Name: PRM.L - Any Technical EventsAlert Criteria: PRM.L (LSE); Classic Patterns; Short-term Patterns; Indicators; Oscillators; Any Opportunity Type (Bullish or Bearish); Daily and Weekly Events. Symbol Exchange Name Event Close at Event Target Price Range Opportunity TypePRM.L LSE Proteome Sciences PLC Price Crosses Moving Average (21-week)W 5.00 n/a Intermediate-Term BullishPRM.L LSE Proteome Sciences PLC Williams %RW 5.00 n/a Short-Term BullishIn view of Dr Pike's and now Diggle's share purchases, it would seem that confidence has returned. 8p therefore would seem a strong possibility.Good luck with OXB!
The Potter
28 Apr 2017
Would you believe it? PRM have done it again!For the second time director buys announced late Friday afternoon:The Company has received notification from Vulpes Life Sciences Fund ("Vulpes"
that on 27 April 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares" at a price of 5p per Ordinary Share (the "Purchase". Following the Purchase Vulpes has a total direct and indirect interest in 54,043,715 equivalent to 18.34% of Proteome Sciences' total issued share capital.The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,043,715 Ordinary Shares of the Company representing 18.34% of the issued share capital of the Company.Do they need a PR expert to explain that this is bad timing?
Ctrl-Alt-Delete
26 Apr 2017
Trading Update With reference to the "transformational" expectations and the fear that this is just another CP exaggeration, it's worth pointing out how far CP has exited from the management of the Company. He currently attends the office 3/4 times a month. In terms of writing company announcements, I believe his involvement is minimal leading me to believe that JH is the author of the statement and driver behind the company. The change in the management's approach to shareholder contact has been significant; no longer do shareholders have easy access to the (old) Chief Executive (thank goodness) being replaced with a 'say less, produce more' approach. Long term holders, of which I am one, will hope that this will produce both an improvement in trading performance and shareholder sentiment to the ultimate benefit of all shareholders.
